(Rac)-Salvianic acid A (sodium)

(Rac)-Salvianic acid A sodium is the racemic form of Salvianic acid A (HY-N1913). Salvianic acid A is an orally active phenolic compound that induces Nrf2/HO-1 activation and inhibits the NF-κB pathway, and it also activates the mitochondrial antioxidant defense system (Mitochondrial Metabolism). Salvianic acid A exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties (Apoptosis), demonstrating potential for research into inflammation and cardiovascular diseases^{[1][2][3][4][5][6][7]}. In Vitro:Salvianic acid A (6-36 μM, 24 h) inhibits the decrease in vascular endothelial cell viability induced by Lipopolysaccharide (HY-D1056) in a dose-dependent manner^[6].
Salvianic acid A (10 or 20 μM, 24 h) inhibits Lipopolysaccharide (HY-D1056)-induced apoptosis through regulating glutathione peroxidase activity and malondialdehyde level in vascular endothelial cells^[6].
Salvianic acid A sodium (25 or 50 μM, 24 h) protects human umbilical vein endothelial cells against tert-butyl hydroperoxide induced oxidative injury via mitochondria-dependent pathway^[7].
In Vivo:Salvianic acid A (3 or 10 mg/kg, p.o., once daily for 6 weeks) suppresses inflammatory reactions and inhibits oxidative stress in atherosclerosis (AS) rats induced by a high-fat diet, showing protective effects against atherosclerosis^[5].